Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria Induction:~* Male or female ≥ 18 years of age.~* Established diagnosis of UC.~* Moderate to severe active left-sided UC assessed by central reading.~* Have inadequate response, loss of response or be intolerant of at least one of the following treatments: Oral GCS, AZA/6-MP, Biologics, JAK-inhibitors, or other approved advanced therapies for UC.~* Allowed to receive a therapeutic dose of the following UC drugs during the study: Oral GCS therapy (≤20 mg prednisone or equivalent/day) , Oral 5-ASA/SP compounds, AZA/6-MP.~* Ability to understand the treatment, willingness to comply with all study requirements, and ability to provide informed consent.~Exclusion Criteria Induction:~* Suspicion of differential diagnosis.~* Acute fulminant UC and/or signs of systemic toxicity.~* UC limited to the rectum or extending beyond the splenic flexure.~* Have failed treatment with more than three advanced therapies of two different therapeutic classes.~* Have had surgery for treatment of UC.~* History of malignancy, unless treated with no relapse of the disease and ≥ 5 years since last treatment (cured).~* History or presence of any clinically significant disorder.~* Concomitant treatment with cyclosporine, methotrexate, tacrolimus, or advanced therapies or similar immunosuppressants and immunomodulators.~* Treatment with rectal GCS, 5-ASA/SP or tacrolimus.~* Long-term treatment (\>14 days) with antibiotics or NSAIDs .~* Serious known active infection including history of latent or active tuberculosis.~* Gastrointestinal infections including positive Clostridium difficile stool assay.~* Females who are lactating or have a positive serum pregnancy test.~* Women of childbearing potential not using highly effective contraceptive methods.~* Concurrent participation in another clinical study.~* Previous exposure to cobitolimod.~Inclusion Criteria Maintenance:~* Participants are eligible to be included in the maintenance study if they have achieved clinical response at week 6 and have adhered to the protocol procedures of the induction study.~Exclusion Criteria Maintenance:~* Participants will not be eligible for the maintenance study if they are not willing to comply with all further study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobitolimod 250 mg (Type: EXPERIMENTAL): Dose of 250 mg cobitolimod~2 treatments during induction study and subsequently every third week
- Cobitolimod 500 mg (Type: EXPERIMENTAL): Dose of 500 mg cobitolimod~2 treatments during induction study and subsequently every third week
- Placebo (Type: PLACEBO_COMPARATOR): Dose of Placebo~2 treatments during induction study and subsequently every third week

Based on this trial design, predict the completion outcome and termination type (if applicable).